S&P 500

6.114,63

-0,01%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Pfizer Inc (PFE)
Pfizer Inc (PFE) Notícias

PFE

Pfizer (PFE)

Pfizer Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NYSE:PFE

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
14/02/2025	19:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:PFE	Pfizer Inc
14/02/2025	16:08	Edgar (US Regulatory)	Form 13F-HR - Quarterly report filed by institutional managers, Holdings	NYSE:PFE	Pfizer Inc
13/02/2025	12:00	Business Wire	Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer	NYSE:PFE	Pfizer Inc
13/02/2025	11:13	PR Newswire (Canada)	ViiV Soins de santé et l'Alliance pharmaceutique pancanadienne (APP) concluent les négociations avec succès concernant APRETUDE pour la prophylaxie préexposition au VIH-1	NYSE:PFE	Pfizer Inc
13/02/2025	11:10	PR Newswire (Canada)	ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis	NYSE:PFE	Pfizer Inc
12/02/2025	16:51	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NYSE:PFE	Pfizer Inc
12/02/2025	14:15	Business Wire	U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	NYSE:PFE	Pfizer Inc
10/02/2025	19:00	Business Wire	Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)	NYSE:PFE	Pfizer Inc
04/02/2025	10:11	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:PFE	Pfizer Inc
04/02/2025	08:45	Business Wire	Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance	NYSE:PFE	Pfizer Inc
03/02/2025	08:45	Business Wire	Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial	NYSE:PFE	Pfizer Inc
28/01/2025	08:45	Business Wire	Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium	NYSE:PFE	Pfizer Inc
25/01/2025	17:00	Business Wire	Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	NYSE:PFE	Pfizer Inc
21/01/2025	20:26	Edgar (US Regulatory)	Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	NYSE:PFE	Pfizer Inc
10/01/2025	08:45	Business Wire	Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer	NYSE:PFE	Pfizer Inc
06/01/2025	12:00	Business Wire	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference	NYSE:PFE	Pfizer Inc
20/12/2024	16:03	Business Wire	U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer	NYSE:PFE	Pfizer Inc
19/12/2024	12:00	Business Wire	Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts	NYSE:PFE	Pfizer Inc
18/12/2024	11:03	IH Market News	Dow May Regain Ground After Longest Losing Streak Since 1978	NYSE:PFE	Pfizer Inc
17/12/2024	18:38	IH Market News	Dow Extends Losing Streak To Nine Days, Nasdaq Pulls Back Off Record High	NYSE:PFE	Pfizer Inc
17/12/2024	08:45	Business Wire	Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance	NYSE:PFE	Pfizer Inc
12/12/2024	19:25	Business Wire	Pfizer Declares First-Quarter 2025 Dividend	NYSE:PFE	Pfizer Inc
12/12/2024	10:15	Business Wire	Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer	NYSE:PFE	Pfizer Inc
10/12/2024	12:00	Business Wire	Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance	NYSE:PFE	Pfizer Inc
10/12/2024	11:05	GlobeNewswire Inc.	Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium	NYSE:PFE	Pfizer Inc
05/12/2024	19:06	Business Wire	Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS	NYSE:PFE	Pfizer Inc
20/11/2024	08:45	Business Wire	Pfizer Announces New Chief Scientific Officer and President, Research & Development	NYSE:PFE	Pfizer Inc
20/11/2024	06:00	Business Wire	European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors	NYSE:PFE	Pfizer Inc
29/10/2024	10:09	IH Market News	Futures Pointing To Modestly Lower Open On Wall Street	NYSE:PFE	Pfizer Inc
29/10/2024	07:45	Business Wire	Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance	NYSE:PFE	Pfizer Inc